Question 1
A 35-year-old female with a newly diagnosed focal epilepsy is being initiated on antiepileptic therapy. Her medical history includes depression for which she is currently taking sertraline. Which of the following antiepileptics should be avoided due to potential exacerbation of her depression?
A. Carbamazepine
B. Levetiracetam
C. Lamotrigine
D. Valproate
E. Topiramate
Rationale: The drug is associated with neuropsychiatric side effects including depression and cognitive effects, making it a less favorable option for patients with a history of depression. Lamotrigine, on the other hand, has mood-stabilizing properties and may be beneficial in patients with mood disorders. Carbamazepine, levetiracetam, and valproate do not have as strong a link with exacerbation of depression as topiramate does.
Question 2
A 24-year-old male with generalized epilepsy is experiencing breakthrough seizures on his current regimen of valproate. He reports adherence to therapy and denies any recent changes in medication, diet, or lifestyle. Which additional antiepileptic drug could be considered for adjunctive therapy?
A. Phenobarbital
B. Ethosuximide
C. Gabapentin
D. Lacosamide
E. Felbamate
Rationale: The drug is a suitable option for adjunctive therapy in the treatment of generalized epilepsy, offering a different mechanism of action to valproate that can be synergistic. Ethosuximide is primarily used for absence seizures, gabapentin is more effective in focal seizures, and phenobarbital has significant sedative side effects. Felbamate is reserved for severe refractory epilepsy due to its risk profile, including aplastic anemia and liver failure.
Question 3
A 29-year-old woman with epilepsy is planning to conceive. She is currently well-controlled on her medication. Which antiepileptic drug is considered safest during pregnancy?
A. Valproate
B. Topiramate
C. Lamotrigine
D. Phenobarbital
E. Carbamazepine
Rationale: The drug is considered one of the safer options for epilepsy control during pregnancy due to its lower risk of teratogenic effects compared to other antiepileptics. Valproate and topiramate are associated with a higher risk of major congenital malformations and are generally avoided. Phenobarbital and carbamazepine carry risks as well, though not as high as valproate or topiramate.
Question 4
A patient diagnosed with focal seizures has been started on carbamazepine. After a week, the patient reports experiencing dizziness and ataxia. What is the most appropriate initial action to manage these side effects?
A. Discontinue carbamazepine immediately.
B. Decrease the dose of carbamazepine.
C. Switch to valproate.
D. Add on gabapentin to counteract the side effects.
E. Check carbamazepine serum level.
Rationale: Dizziness and ataxia are common side effects of carbamazepine, often related to high plasma levels. Before adjusting the dose, it’s important to check the serum level to determine if it’s within the therapeutic range. If levels are high, a dose reduction may be warranted. Discontinuation or switching medications should be considered only if side effects persist or are intolerable at therapeutic levels.
Question 5
A patient with epilepsy is being treated with phenytoin. Upon routine monitoring, the patient’s phenytoin serum concentration is found to be 32 mg/L (therapeutic range: 10-20 mg/L). Which of the following symptoms is the patient most likely to exhibit?
A. Hypoglycemia
B. Nystagmus
C. Hypertension
D. Tachycardia
E. Diarrhea
Rationale: This is a common side effect of phenytoin toxicity, especially when serum levels exceed the therapeutic range. Other signs of phenytoin toxicity include ataxia, dizziness, and mental confusion. Hypoglycemia, hypertension, tachycardia, and diarrhea are not typically associated with elevated phenytoin levels.
Question 6
A 40-year-old male with a history of tonic-clonic seizures is on phenytoin therapy. He presents to the clinic with gingival hyperplasia. Which of the following interventions is most appropriate for managing this side effect?
A. Switch to carbamazepine.
B. Initiate folic acid supplementation.
C. Increase phenytoin dose to quicken seizure control and reduce duration of therapy.
D. Recommend regular dental check-ups and oral hygiene.
E. Discontinue phenytoin immediately and start levetiracetam.
Rationale: Gingival hyperplasia is a known side effect of phenytoin. Management includes good oral hygiene, regular dental check-ups, and sometimes surgical intervention if severe. Folic acid supplementation is beneficial in pregnant women to reduce the risk of neural tube defects but is not directly beneficial for gingival hyperplasia. Switching antiepileptics or adjusting doses should be considered if the side effect is severe and negatively impacting the patient’s quality of life, but it is not the first step.
Question 7
A 30-year-old female with newly diagnosed absence seizures is evaluating treatment options with her healthcare provider. Which of the following medications is considered first-line therapy for absence seizures?
A. Gabapentin
B. Ethosuximide
C. Lacosamide
D. Carbamazepine
E. Lamotrigine
Rationale: The drug is considered the first-line treatment for absence seizures due to its efficacy in suppressing the typical 3 Hz spike-and-wave discharges seen on EEG during absence seizures. Gabapentin and lacosamide are more commonly used for focal seizures, carbamazepine can exacerbate absence seizures, and while lamotrigine is also effective for absence seizures, ethosuximide is preferred due to its specific efficacy and tolerability profile for this seizure type.
Question 8
A 55-year-old man with a history of focal seizures is taking phenytoin and experiences a steady state serum concentration at the higher end of the therapeutic range. He is also diagnosed with osteoporosis. Which of the following factors is most likely contributing to his osteoporosis?
A. Phenytoin-induced vitamin D metabolism
B. Direct bone marrow suppression by phenytoin
C. Phenytoin-induced hypocalcemia
D. Increased bone turnover due to phenytoin
E. Phenytoin’s effect on calcium absorption in the intestine
Rationale: The drug induces cytochrome P450 enzymes, which increases the metabolism of vitamin D, leading to decreased calcium absorption, secondary hyperparathyroidism, and bone loss, contributing to osteoporosis. While phenytoin may also cause hypocalcemia and increased bone turnover, these are consequences of its effect on vitamin D metabolism. Direct bone marrow suppression and effects on calcium absorption in the intestine are not the primary mechanisms by which phenytoin contributes to osteoporosis.
Question 9
A patient with refractory epilepsy is considering treatment options after failing two first-line antiepileptic drugs. Which of the following medications is most likely to be effective as a third option?
A. Phenobarbital
B. Clobazam
C. Pregabalin
D. Oxcarbazepine
E. Felbamate
Rationale: The drug is considered an option for patients with refractory epilepsy who have not responded to first-line treatments, due to its broad spectrum of action and potential efficacy in difficult-to-control seizures. However, due to its risk of aplastic anemia and hepatic failure, it is typically reserved for use when other treatments have failed and with careful monitoring. Phenobarbital, clobazam, pregabalin, and oxcarbazepine may also be used in the treatment of epilepsy but may not offer the same potential benefit in refractory cases as felbamate.
Question 10
A patient who has been taking valproate for seizure control is undergoing routine blood work. The results indicate thrombocytopenia. Which of the following is the most appropriate management strategy for this patient’s condition?
A. Discontinue valproate immediately.
B. Reduce the dose of valproate and monitor platelet levels.
C. Supplement with vitamin K.
D. Switch to levetiracetam.
E. Monitor patient without any change to valproate therapy.
Rationale: The drug can cause dose-dependent thrombocytopenia. If thrombocytopenia is detected, reducing the dose and closely monitoring platelet levels is an appropriate management strategy, especially if valproate is effective in controlling seizures and other options may not be as effective or may cause significant side effects. Discontinuing valproate immediately is only necessary if the thrombocytopenia is severe or symptomatic. Supplementing with vitamin K is not a standard treatment for valproate-induced thrombocytopenia. Switching to another antiepileptic drug, such as levetiracetam, might be considered if thrombocytopenia persists or if the patient has other side effects from valproate, but it’s not the first step.